Chronic Kidney Disease

The American Kidney Fund applauded provisions made within the Build Back Better Act that are designed to help Americans with chronic kidney disease and kidney failure, according to a press release.

Researchers successfully used electronic health record data to measure and identify risk factors of chronic kidney disease progression in a large cohort of pediatric patients, according to a speaker at ASN Kidney Week.

Urinary VEGF levels were lower in premature infants with severe lung disease who developed chronic kidney disease compared with those who did not develop CKD, implying VEGF may be a biomarker of CKD in this patient population.

For patients with chronic kidney disease, dapagliflozin slowed long-term decreases in the eGFR.

The investigational drug, bardoxolone methyl preserved kidney function in patients and provided eGFR benefits for those with chronic kidney disease, according to an oral abstract presentation given as part of ASN Kidney Week.

Saghmos Therapeutics Inc. announced the issuance of the U.S. Patent No. 11,123,345 for its product ST-62516, also known as trimetazidine, along with its plans for a phase 3 study of the drug.

For patients with advanced chronic kidney disease, gout can significantly increase health care utilization and comorbidities, according to a study presented at ASN Kidney Week.

In this video, Craig A. Shadur, MD, a transplant nephrologist from Des Moines, Iowa, discussed the use of pegloticase for patients with kidney transplants.

When treated with direct-acting antiviral therapy, patients with chronic hepatitis C virus infection were at a lower risk for end-stage kidney disease and the composite of ESKD or death, according to a speaker at ASN Kidney week.

Increased exposure to air pollution may lead to higher risk for myocardial fibrosis in patients with chronic kidney disease, according to a speaker at ASN Kidney Week.